Immune Design said an interim analysis of its ongoing, randomized phase II trial showed that NY-ESO-1+ soft tissue sarcoma patients receiving the combination of CMB305 and Genentech’s checkpoint inhibitor, atezolizumab (Tecentriq), experienced greater clinical benefit and immune response than those receiving atezolizumab alone.
FDA granted full approval of Tecelra (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.Â
